KRAS and colorectal carcinoma: We found that there were 24 KRAS-mutant CRC patients accounting for 37.5% in 64 cases (Supplementary Table 1) and no significant difference of RNF141 protein level between KRAS-mutant and KRAS-wildtype CRC tissues (P > 0.05) (Fig. s5D).